vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Fat Brands, Inc (FAT). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $140.0M, roughly 1.2× Fat Brands, Inc). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -2.3%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -6.1%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
FAT Brands Inc. is an American multi-brand restaurant and sports bar franchise operator headquartered in Beverly Hills, California.
ESPR vs FAT — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $140.0M |
| Net Profit | — | $-58.2M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | -12.4% |
| Net Margin | — | -41.6% |
| Revenue YoY | 143.7% | -2.3% |
| Net Profit YoY | — | -30.1% |
| EPS (diluted) | $0.32 | $-3.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | — | ||
| Q3 25 | $87.3M | $140.0M | ||
| Q2 25 | $82.4M | $146.8M | ||
| Q1 25 | $65.0M | $142.0M | ||
| Q4 24 | $69.1M | $145.3M | ||
| Q3 24 | $51.6M | $143.4M | ||
| Q2 24 | $73.8M | $152.0M | ||
| Q1 24 | $137.7M | $152.0M |
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $-58.2M | ||
| Q2 25 | $-12.7M | $-54.2M | ||
| Q1 25 | $-40.5M | $-46.0M | ||
| Q4 24 | — | $-67.4M | ||
| Q3 24 | $-29.5M | $-44.8M | ||
| Q2 24 | $-61.9M | $-39.4M | ||
| Q1 24 | $61.0M | $-38.3M |
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | -12.4% | ||
| Q2 25 | 8.6% | -10.6% | ||
| Q1 25 | -34.0% | -6.0% | ||
| Q4 24 | -6.4% | -27.1% | ||
| Q3 24 | -31.0% | -6.2% | ||
| Q2 24 | 3.5% | -1.8% | ||
| Q1 24 | 52.5% | -0.9% |
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | -41.6% | ||
| Q2 25 | -15.4% | -36.9% | ||
| Q1 25 | -62.2% | -32.4% | ||
| Q4 24 | — | -46.4% | ||
| Q3 24 | -57.2% | -31.2% | ||
| Q2 24 | -83.9% | -25.9% | ||
| Q1 24 | 44.3% | -25.2% |
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | $-3.39 | ||
| Q2 25 | $-0.06 | $-3.17 | ||
| Q1 25 | $-0.21 | $-2.73 | ||
| Q4 24 | $-0.14 | $-4.06 | ||
| Q3 24 | $-0.15 | $-2.74 | ||
| Q2 24 | $-0.33 | $-2.43 | ||
| Q1 24 | $0.34 | $-2.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | $1.3B |
| Stockholders' EquityBook value | $-302.0M | $-585.8M |
| Total Assets | $465.9M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — | ||
| Q1 24 | $226.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $-302.0M | — | ||
| Q3 25 | $-451.4M | $-585.8M | ||
| Q2 25 | $-433.5M | $-536.5M | ||
| Q1 25 | $-426.2M | $-493.9M | ||
| Q4 24 | $-388.7M | $-455.7M | ||
| Q3 24 | $-370.2M | $-386.1M | ||
| Q2 24 | $-344.2M | $-338.6M | ||
| Q1 24 | $-294.3M | $-296.8M |
| Q4 25 | $465.9M | — | ||
| Q3 25 | $364.0M | $1.2B | ||
| Q2 25 | $347.1M | $1.2B | ||
| Q1 25 | $324.0M | $1.3B | ||
| Q4 24 | $343.8M | $1.3B | ||
| Q3 24 | $314.1M | $1.3B | ||
| Q2 24 | $352.3M | $1.4B | ||
| Q1 24 | $373.1M | $1.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $-14.5M |
| Free Cash FlowOCF − Capex | — | $-16.9M |
| FCF MarginFCF / Revenue | — | -12.1% |
| Capex IntensityCapex / Revenue | 0.0% | 1.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-75.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | — | ||
| Q3 25 | $-4.3M | $-14.5M | ||
| Q2 25 | $-31.4M | $-26.9M | ||
| Q1 25 | $-22.6M | $-13.2M | ||
| Q4 24 | $-35.0M | $-10.4M | ||
| Q3 24 | $-35.3M | $-3.2M | ||
| Q2 24 | $-7.2M | $-14.2M | ||
| Q1 24 | $53.8M | $-28.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-16.9M | ||
| Q2 25 | — | $-29.3M | ||
| Q1 25 | — | $-17.8M | ||
| Q4 24 | — | $-11.0M | ||
| Q3 24 | $-35.5M | $-11.1M | ||
| Q2 24 | $-7.3M | $-24.4M | ||
| Q1 24 | $53.8M | $-32.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | -12.1% | ||
| Q2 25 | — | -20.0% | ||
| Q1 25 | — | -12.5% | ||
| Q4 24 | — | -7.6% | ||
| Q3 24 | -68.7% | -7.7% | ||
| Q2 24 | -9.9% | -16.1% | ||
| Q1 24 | 39.0% | -21.4% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.6% | ||
| Q1 25 | 0.0% | 3.2% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.3% | 5.5% | ||
| Q2 24 | 0.1% | 6.7% | ||
| Q1 24 | 0.1% | 2.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
FAT
| Restaurant Sales | $96.6M | 69% |
| Royalty | $21.6M | 15% |
| Factory | $9.6M | 7% |
| Advertising | $9.1M | 7% |
| Franchisor | $1.5M | 1% |
| Other | $1.5M | 1% |
